OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models.
Fabre M, Ferrer C, Domínguez-Hormaetxe S, Bockorny B, Murias L, Seifert O, Eisler SA, Kontermann RE, Pfizenmaier K, Lee SY, Vivanco MD, López-Casas PP, Perea S, Abbas M, Richter W, Simon L, Hidalgo M.
Fabre M, et al. Among authors: eisler sa.
Clin Cancer Res. 2020 Jul 1;26(13):3420-3430. doi: 10.1158/1078-0432.CCR-19-2238. Epub 2020 Mar 11.
Clin Cancer Res. 2020.
PMID: 32161121